Monday, May 10, 2021

Kristen Nichols

132 POSTS0 COMMENTS

Acreage Hempco parent company names Pfizer alum new CEO

A multistate marijuana company with properties including Acreage Hempco — Acreage Holdings Inc. — has appointed Peter Caldini as chief executive officer. Caldini has experience in both healthcare and consumer packaged goods, having served as president of pharmaceutical giant Pfizer’s divisions in North America and Europe, the Middle East and Africa, as well as working as a brand manager for consumer packaged goods giant Unilever. More recently, Caldini worked as CEO of special purpose acquisition corporation Bespoke Capital Acquisition Corp. He takes the helm at New York-based Acreage on Dec. 21. Acreage is based in New York and trades on the Canadian Securities Exchange as ACRG.U and on U.S. over-the-counter markets as ACRGF.

DEA wins latest round against hemp operators in extraction case

A federal judge has rejected legal maneuvers by the Hemp Industries Association and a South Carolina CBD maker trying to get the U.S. Drug Enforcement Administration to clarify whether it considers temporary byproducts of hemp production a Schedule 1 substance. In an order Tuesday by the U.S. District Court in Washington DC, Judge James Boasberg said that HIA and RE Botanicals were acting in an “unusual manner” to get the DEA to answer advance questions about a rule the agency issued in August that criminalizes common byproducts of cannabinoid extraction. The rule is in effect, though the DEA has yet to enforce it. The judge said the DEA shouldn’t have to explain its position before the lawsuit goes to trial. At issue is whether the DEA is simply updating its policies to comply with the 2018 Farm Bill, which removed low-THC cannabis from the Controlled Substances Act, or whether the DEA is making an illegal power grab by saying that hemp extracts are Schedule 1 controlled substances during a portion of the extraction process when the plant’s THC levels spike above what’s allowed. The latest motion in the case was first reported by Law 360.

FTC announces first monetary sanctions for CBD medical claims, says to expect more

The U.S. Federal Trade Commission announced its first crackdown on deceptive claims in the CBD market Thursday, issuing fines and sanctions to six manufacturers accused of misleading consumers about the health benefits of the cannabis extract. The FTC, an independent government agency charged with consumer protection, says the six companies made illegal claims about their products’ ability to treat diseases including cancer, high blood pressure and Alzheimer’s disease. “We are not saying that CBD products cannot provide some relief to some patients,” Andrew Smith, director of the FTC’s Bureau of Consumer Protection, told reporters after announcing the sanctions. “But the same rules of the road apply to CBD products that apply to all other health products. In no event can they exaggerate or lie about the state of the science.” The sanctioned CBD makers were: Bionatrol Health and Isle Revive of Pleasant Grove, Utah. The company was ordered to pay $20,000. Epichouse (First Class Herbalist) of West Valley City, Utah. The company was ordered to pay $30,000. CBD Meds Inc. of Winchester, California. The company was ordered to stop making unproven claims. Easybutter and HempmeCBD of Boca Raton, Florida. The company was ordered to pay $36,254. Reef Industries and CannaTera of Costa Mesa, California. The company was ordered to pay $85,000. Steves Distributing of Longmont, Colorado. The company was ordered to pay $75,000. The FTC cited illegal advertising claims made by each of the manufacturers. Claims included promises that taking CBD would “leav(e) you pain free and feeling years younger.” Many included customer testimonials saying the products cured rare ailments or replaced prescription drugs, including OxyContin. Screen shot from a sanctioned CBD manufacturer (image courtesy FTC) Each of the companies is also required to notify consumers within 45 days of the FTC sanctions. They do that by emailing anyone who bought the products an email with the subject line, “About Your Purchase from [company name].” The companies then must submit a report to the FTC within 90 days summarizing their actions, including the total number of eligible customers identified and notified. The agency said the CBD industry could expect more actions in the future when unsubstantiated medical claims are made. “Don’t make spurious health claims that are unsupported by medical science,” Smith said in a statement. “Otherwise, don’t be surprised if you hear from the FTC.” Thursday’s actions were the FTC’s first monetary sanctions against CBD makers, but not the first enforcement of advertising rules. In April, the FTC announced a settlement with the owner of Whole Leaf Organics to stop touting three CBD treatments as an “anti-viral wellness booster.” Learn more from FTC and FDA attorneys about legal compliance in the CBD industry at MJBizCon2020, now available on demand. Kristen Nichols can be reached at [email protected]

Study: Consumers don’t know CBD and THC levels in cannabis products

THC distililate oil is displayed at PharmaCann Polska's EU-GMP certified subsidiary, known as NYSK, in North Macedonia. - Photo courtesy PharmaCann This story originally appeared at Marijuana Business Daily. A new study shows consumers are unable to identify cannabinoid levels in products they use. Further, 20% to 50% don’t know the THC:CBD ratio of the products they normally use. This lack of consumer awareness could have implications for the safety and efficacy of therapeutic use and throws into question the reliance on self-reported cannabis potency in scientific studies. The research, carried out at the University of Waterloo in Ontario, aimed to gauge consumer understanding of THC and CBD levels of common cannabis products, including herbal cannabis, edibles, vaporizers and topicals. Data was collected online over a two-month period in 2018 from consumers in three jurisdictions: in Canada, prior to the legalization of recreational cannabis; in U.S. states in which recreational cannabis was prohibited; and in U.S. states that had legalized nonmedical cannabis. Of those reporting use of dried cannabis, only 10% were able to report the THC level of products they usually consumed. In all three jurisdictions, less than one-third of consumers were able to identify THC and CBD levels in their products. While the study did not verify the accuracy of this self-reported data, many consumers said their products contained implausible amounts of THC (greater than 30%) or CBD (greater than 20%)—levels rarely seen in the market. Confusion about units of measurement was also prevalent, with consumers of dried cannabis reporting THC levels in milligrams (instead of grams) and users of edibles identifying cannabinoid levels in percentages (instead of milligrams). While users in U.S. states where marijuana is legal were better able to report THC and CBD levels, still less than 20% of those using dried marijuana could identify THC levels. These findings are consistent with other studies of self-reported THC levels that correlated only modestly with laboratory-tested levels. Given the expansion of cannabis products in both recreational and medical markets—including high-CBD products and those with moderate and balanced THC:CBD ratios—there appears to be a need for more consumer education, especially about THC and CBD potency. More-frequent users were better able to report both THC:CBD ratios and levels, suggesting consumer awareness may improve as the industry matures. Read more exclusive data about the smokable hemp market in the free report “Sector Snapshot: Opportunities & Challenges in Smokable Hemp.”

Hemp at 1% THC wins new Senate proposal

A bill to triple the THC limit for hemp grown in the United States has been introduced by Kentucky Sen. Rand Paul.The Republican’s proposal to raise the THC dividing line between hemp and marijuana from 0.3% THC to 1% THC stands little chance of success in the abbreviated lame-duck Congress. But the suggestion reflects widespread concern in the industry that the current THC limit for hemp is too low for a new crop with unstable genetics. The bill would also raise the THC limit for hemp byproducts such as extracted oils. Products with more than 1% THC would remain illegal Schedule 1 substances. Also, the proposal would allow farmers to have the final hemp products tested, not the raw plant material, opening the door for mitigating hot hemp. “There is still work to do to prevent the federal government from weighing down our farmers with unnecessary bureaucratic micromanaging,” Paul said in a statement. Paul’s bill would add a requirement that hemp shipments be accompanied by certificates saying that the products are legal. Paul’s suggestion comes less than a month after Texas Agriculture Commissioner Sid Miller, himself a hemp grower, called on Congress to raise the THC limit, calling 0.3% “way, way too low.” The Senate has another pending measure approved by its House counterparts this month to take all varities of cannabis out of the U.S. Controlled Substances Act. That proposal passed the House 228-164 but has seen no action by the Senate. Both proposals die next month, when a new Congress is seated and must begin taking up new legislation.

Brazil postpones evaluation of CBD formulation for medical coverage

(A version of this story originally appeared at Marijuana Business Daily International.) A government evaluation to include a CBD product in Brazil’s Public Health System has been postponed. Brazil’s National Committee for Health Technology Incorporation had been scheduled to take up the question of covering the oral CBD product this week. Instead, the evaluation will now occur in early 2021. A decision to include the CBD formulation in Brazil’s national health insurance scheme would be a game-changer for the local industry, as it would effectively make CBD free to patients. Over-the-counter CBD food products or supplements are currently illegal on the Brazilian market. Tarso Araujo, chief business development officer for São Paulo-based Entourage Phytolab told Hemp Industry Daily he’d be “surprised” if a CBD product is included in public coverage without finished clinical trials proving its safety and efficacy. “Moreover, its high price doesn’t help pass the cost-benefit consideration,” Araujo said. Brazil’s health agency could take up the issue again as soon as February, according to Brazilian cannabis news website Sechat. The product set to be evaluated is manufactured by Brazilian pharmaceutical firm Prati-Donaduzzi with imported raw material. It is the only medical cannabis product that has received “sanitary authorization” from Brazil’s National Sanitary Surveillance Agency. Alfredo Pascual can be reached at [email protected]

TOP AUTHORS

0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
286 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
3 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
6 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
20 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
11 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
3 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
31 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
132 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
74 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
14 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
5 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
4 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
13 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
23 POSTS0 COMMENTS
45 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
109 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
6 POSTS0 COMMENTS
2 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
1 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS
0 POSTS0 COMMENTS